TransMedics Group (NASDAQ:TMDX) Announces Quarterly Earnings Results, Beats Expectations By $0.21 EPS

TransMedics Group (NASDAQ:TMDX) released its earnings results on Thursday. The company reported $0.51 earnings per share for the quarter, beating the consensus estimate of $0.30 by $0.21, FiscalAI reports. TransMedics Group had a net margin of 22.69% and a return on equity of 15.88%. The firm had revenue of $203.01 million during the quarter, compared to analyst estimates of $178.06 million.

Here are the key takeaways from TransMedics Group’s conference call:

• TransMedics reported a record $203 million in third-quarter revenue, up 41% year over year, with liver and heart case volumes rising despite seasonal softness and a 6% decline in U.S. deceased-donor volume. The company raised 2026 revenue guidance to $764 million–$774 million, including about $14 million from PAD Aviation.
• Management highlighted upcoming growth opportunities in heart and lung: FDA approved protocol amendments for ENHANCE Heart Part B and DENOVO Lung, with enrollment expected to begin in early 2027. The company also remains on track for OCS Kidney’s first-in-human clinical experience in the second half of 2027, though these programs have not yet contributed meaningful revenue.
• TransMedics won its first European transplant-logistics tender, in Italy’s Emilia-Romagna region, and plans to launch OCS NOP in Italy, the Netherlands, and Belgium in the first half of 2027. Management sees additional tenders as a potential source of growth, but did not quantify the first award.
• Third-quarter GAAP gross margin was not specified, but reported gross margin was 58.5%, down 40 basis points year over year, partly because lower-margin service revenue and PAD Aviation made up a larger share of sales. Excluding PAD, gross margin improved to 61.1%; management expects some normalization in service margins in the fourth quarter and kept its full-year adjusted operating-margin outlook at 12.5%–14% amid planned investment.
• Executives acknowledged softer October flight trends and said fourth-quarter guidance assumes no meaningful revenue contribution from ENHANCE Part B or DENOVO, as well as potential holiday-season effects. They characterized the outlook as conservative and said recent flight data alone may not reflect total transport activity.

TransMedics Group Price Performance

NASDAQ:TMDX traded down $3.77 during trading hours on Thursday, reaching $68.98. 1,677,502 shares of the company’s stock were exchanged, compared to its average volume of 1,006,112. The company has a market capitalization of $2.38 billion, a P/E ratio of 17.73, a price-to-earnings-growth ratio of 0.93 and a beta of 2.14. TransMedics Group has a 12 month low of $60.10 and a 12 month high of $156.00. The company has a quick ratio of 6.07, a current ratio of 6.62 and a debt-to-equity ratio of 1.62. The business’s 50-day simple moving average is $79.68 and its two-hundred day simple moving average is $93.44.

Insider Transactions at TransMedics Group

In other TransMedics Group news, Director David Weill purchased 1,336 shares of the firm’s stock in a transaction on Friday, September 11th. The shares were purchased at an average price of $81.63 per share, for a total transaction of $109,057.68. Following the completion of the transaction, the director owned 16,392 shares in the company, valued at $1,338,078.96. This represents a 8.87% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 6.90% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Weiss Ratings raised shares of TransMedics Group from a “hold (c-)” rating to a “hold (c)” rating in a research note on Monday, August 31st. Piper Sandler reissued an “overweight” rating and set a $100.00 target price (down from $120.00) on shares of TransMedics Group in a report on Wednesday, August 5th. Barclays initiated coverage on TransMedics Group in a research note on Wednesday, October 7th. They set an “overweight” rating and a $120.00 price target for the company. TD Cowen reaffirmed a “buy” rating and set a $120.00 price target on shares of TransMedics Group in a research note on Tuesday, September 8th. Finally, Needham & Company LLC reiterated a “buy” rating on shares of TransMedics Group in a research report on Friday, September 11th. Five research analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $115.60.

About TransMedics Group

TransMedics Group, Inc is a medical technology company focused on improving organ transplantation through systems that preserve and assess donor organs outside the body. The company’s primary platform is the Organ Care System (OCS), a portable, technology-enabled perfusion system designed to maintain organs in a functioning, near-physiologic state during transport and evaluation.

TransMedics offers OCS products for heart, lung and liver transplantation. Its systems are intended to support the use of organs that may not otherwise be suitable for conventional cold-storage methods, potentially expanding the donor pool and providing transplant teams with additional information when evaluating organs for transplantation.

Founded in 1998 and headquartered in Andover, Massachusetts, TransMedics serves transplant centers in the United States and select international markets.